David Stanley Bailey
Fondateur chez IOTA Pharmaceuticals Ltd.
Profil
David Stanley Bailey was the founder of De Novo Pharmaceuticals Ltd.
(founded in 1999), Purely Proteins Ltd.
(founded in 2002), and IOTA Pharmaceuticals Ltd.
(founded in 2007) where he held the titles of Chief Executive Officer and Director.
He also held former positions as a Principal at Incyte Corp.
and Pfizer Inc., as well as at the University of London.
Dr. Bailey received a doctorate degree from the University of Cambridge.
Postes actifs de David Stanley Bailey
| Sociétés | Poste | Début |
|---|---|---|
IOTA Pharmaceuticals Ltd.
 IOTA Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology IOTA Pharmaceuticals Ltd. is a pharmaceutical discovery services company. Its services include virtual screening packages, surface Plasmon resonance (SPR) screening package, high-sensitivity biochemical screening package, nuclear magnetic resonance (NMR) screening package, and co-crystallography of fragment-based leads. The company was founded by Paul England and David Bailey in 2007 and is headquartered in Cambridge, the United Kingdom. | Fondateur | 01/01/2007 |
Anciens postes connus de David Stanley Bailey
| Sociétés | Poste | Fin |
|---|---|---|
De Novo Pharmaceuticals Ltd.
 De Novo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom. | Fondateur | - |
| INCYTE CORPORATION | Corporate Officer/Principal | - |
| University of London | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Purely Proteins Ltd.
 Purely Proteins Ltd. Pharmaceuticals: MajorHealth Technology Purely Proteins Ltd. provided supportive services for drug discovery. The firm also offered range of protein-based tools to aid drug discovery, research and development. The company was founded by David Bailey, Geeta Gupta, Christopher Robin Lowe and David J. Parry-Smith on July 16, 2002 and was headquartered in Madingley, the United Kingdom. | Fondateur | - |
Formation de David Stanley Bailey
| University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
De Novo Pharmaceuticals Ltd.
De Novo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom. | Health Technology |
Purely Proteins Ltd.
Purely Proteins Ltd. Pharmaceuticals: MajorHealth Technology Purely Proteins Ltd. provided supportive services for drug discovery. The firm also offered range of protein-based tools to aid drug discovery, research and development. The company was founded by David Bailey, Geeta Gupta, Christopher Robin Lowe and David J. Parry-Smith on July 16, 2002 and was headquartered in Madingley, the United Kingdom. | Health Technology |
IOTA Pharmaceuticals Ltd.
IOTA Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology IOTA Pharmaceuticals Ltd. is a pharmaceutical discovery services company. Its services include virtual screening packages, surface Plasmon resonance (SPR) screening package, high-sensitivity biochemical screening package, nuclear magnetic resonance (NMR) screening package, and co-crystallography of fragment-based leads. The company was founded by Paul England and David Bailey in 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
